GE HealthCare agreed to buy Sofie Biosciences for $945 million in cash to expand U.S. radiopharmaceutical manufacturing capacity, particularly for time-sensitive PET products. The deal is expected to close in the first half of 2027 and will integrate Sofie into GE HealthCare’s pharmaceutical diagnostics business. Sofie currently operates a U.S. network of 15 contract manufacturing sites and supplies multiple F18-labeled products, including Flyrcado. GE HealthCare said it will also gain U.S. rights to FAPI-74, a pan-cancer PET radiotracer in development. The acquisition is positioned as a way to reduce bottlenecks in the radiopharmaceutical adoption cycle, where short half-life logistics often constrain clinical throughput.